Investigational Drug Information for Vatalanib
✉ Email this page to a colleague
What is the development status for investigational drug Vatalanib?
Vatalanib is an investigational drug.
There have been 24 clinical trials for Vatalanib.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2003.
The most common disease conditions in clinical trials are Neoplasms, Neuroendocrine Tumors, and Carcinoid Tumor. The leading clinical trial sponsors are Novartis, National Cancer Institute (NCI), and Novartis Pharmaceuticals.
Summary for Vatalanib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5,853 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 914 |
| Clinical Trial Progress | Phase 3 (2003-01-01) |
| Vendors | 54 |
Recent Clinical Trials for Vatalanib
| Title | Sponsor | Phase |
|---|---|---|
| Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Phase 1/Phase 2 |
| Apatinib for Metastatic Esophageal Cancer. | Hangzhou Cancer Hospital | Phase 2 |
| Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for Vatalanib
Top disease conditions for Vatalanib
Top clinical trial sponsors for Vatalanib
US Patents for Vatalanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
